Peptides / Immune and antimicrobial

Natural fragment · 14 amino acids · 1,818 Da

Gepon

Approved in Russia

Gepon, also called Hepon, is a synthetic peptide from the protein ezrin, registered in Russia as a topical medicine, with no US or EU approval found. Studies in people tested it mostly against hepatitis C and HIV, and on liver function and the gut. PepBank shows 18 results on gepon from 2 studies in people, and 34 from animal and lab studies. The strongest evidence is a trial in people without random groups. Data as of 2026-10-30.

Also known as HEP-1, Hepon, Heponum, TEKKRRETVEREKE

14 amino acids, from first to lastTEKKRRETVEREKE

Evidence level: Some studies in people18 of 52 results come from studies in people.

Results in people

35% of 52 results

Results in animals

40% of 52 results

Results in lab cells

25% of 52 results

From computer models

0% of 52 results

Overview

Gepon at a glance

What it is	Natural fragment, 14 amino acids
Approval	Approved in Russia only
In sport	Status unknown
Studies	12 studies with results. 7 of them gave gepon, with 52 results. 18 in people21 in animals13 in lab cells
Best study in people	Non-randomized trial with 37 people (2007)
Clinical trials	None registered

The science

What is gepon?

An ezrin-derived peptide used as a registered topical medicine in Russia.

Amino acids in one chain

Gepon structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 14 amino acidsFrom the first amino acid to the last

T1−E+K+K+R5+R−ETV−E10+R−E+K−E

Darker means more water-repelling+ and − show charge in the body

Structure

Gepon is a natural fragment of 14 amino acids, with no ring, no changed amino acids.

Formula

C₇₄H₁₃₂N₂₆O₂₇

Molecular weight

1,818 g/mol

CAS number

174641-44-2

Development

IMMAPHARMA (manufacturer) / Avexima (registration holder). Highest phase: past the trial stage (see status).

Identifiers

PubChem 25078222

Full sequence, SMILES and InChIKey

Three-letter sequence
Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu

InChIKey
HTQONPPEZULJKY-XRBNWYQFSA-N

SMILES
C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O

See charge, composition and 3D structure on the Scientific page

The evidence

What gepon studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Some studies in people18 of 52 results come from studies in people.

Infections

24 results · 13 in people · 5 animal · 6 lab

In the combined studies, 10 of 37 patients had HCV reductions between -7 log and -3 log after HEP1. Arzneimittel-Forschung, 2007

Top results

In the combined studies, 10 of 37 patients had HCV reductions between -7 log and -3 log after HEP1. (Arzneimittel-Forschung, 2007)
In the combined studies, 4 of 37 patients had a -3 log HCV reduction after HEP1. (Arzneimittel-Forschung, 2007)
In the combined studies, 6 of 37 patients had a -2 log HCV reduction after HEP1. (Arzneimittel-Forschung, 2007)

Liver

2 results · 2 in people

In the first study, the response in 16 of 18 patients included normalization of liver enzymes after HEP1. Arzneimittel-Forschung, 2007

Top results

In the first study, the response in 16 of 18 patients included normalization of liver enzymes after HEP1. (Arzneimittel-Forschung, 2007)
In the second study, the response in 8 of 10 patients included normalization of liver enzymes after HEP1. (Arzneimittel-Forschung, 2007)

Immune system and inflammation

14 results · 1 in people · 11 animal · 2 lab

In patients with HCV and HIV, the CD4/CD8 ratio improved with HEP1. Arzneimittel-Forschung, 2007

Top results

In patients with HCV and HIV, the CD4/CD8 ratio improved with HEP1. (Arzneimittel-Forschung, 2007)
In mice with DSS colitis, GEPON reduced Il1b gene activity in colon tissue. (Peptides, 2020)
In mice with DSS colitis, GEPON reduced Il6 gene activity in colon tissue. (Peptides, 2020)

Stomach and gut

3 results · 1 in people · 2 animal

In patients with resistant ulcerative colitis, most (83.3%) improved clinically and on endoscopy after Gepon and overcame resistance to basic anti-inflammatory drugs. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2005

Top results

In patients with resistant ulcerative colitis, most (83.3%) improved clinically and on endoscopy after Gepon and overcame resistance to basic anti-inflammatory drugs. (Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2005)
In mice with DSS colitis, GEPON reduced signs of disease in the large intestine. (Peptides, 2020)
In mice with DSS colitis, GEPON reduced bloody diarrhoea. (Peptides, 2020)

Survival and serious illness

1 result · 1 animal

In mice infected with HSV type 2, Gepon increased average lifespan by 1.9 days. Voprosy virusologii, 2003

Top results

In mice infected with HSV type 2, Gepon increased average lifespan by 1.9 days. (Voprosy virusologii, 2003)

Weight and appetite

1 result · 1 animal

In mice with DSS colitis, GEPON reduced weight loss. Peptides, 2020

Top results

In mice with DSS colitis, GEPON reduced weight loss. (Peptides, 2020)

All 2 studies in people

In people

In the combined studies, 10 of 37 patients had HCV reductions between -7 log and -3 log after HEP1.

2007Arzneimittel-Forschung37 people

In people

In patients with resistant ulcerative colitis, most (83.3%) improved clinically and on endoscopy after Gepon and overcame resistance to basic anti-inflammatory drugs.

2005Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology36 people

All 12 gepon studies by area Open the Scientific page

Key gepon studies

Studies in people come first, then studies in animals and in the lab.

People
Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected patients
Salamov et al. 2007 · Arzneimittel-Forschung · 37 people · cited by 4
17 results
People
[Use of the Gepon immunomodulator for ulcerative colitis treatment]
Malakhova et al. 2005 · Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · 36 people · cited by 1
1 result
Animals
Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G<sup>+</sup> granulocytes and Ly6C<sup>+</sup> monocytes
Chulkina et al. 2020 · Peptides · cited by 9
16 results
Animals
[The antiviral activity of peptide immunomodulator "Gepon" in experimental infections caused by herpes simplex viruses types 1 and 2]
Barinskiĭ et al. 2003 · Voprosy virusologii · cited by 1
6 results
Animals
[The antiviral activity of the peptide immunomodulator "Gepon" in experimental models of street rabies virus]
Gribencha et al. 2003 · Voprosy virusologii · cited by 0
5 results

All 12 Gepon studies

Gepon clinical trials

ClinicalTrials.gov lists no trial of gepon. A trial under another name may exist.

Status and safety

Is gepon approved?

FDA

United States

Status unknown

Status unknown.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

Yes. Approved in Russia only. Status unknown.

Laws and labels change, so check the regulator for the current status.

Gepon side effects and safety

PepBank has 3 safety results from studies of gepon. 1 of them come from studies in people.

Safety results from studies (3)

In patients with HCV and HIV, no adverse reactions or side effects were detected with HEP1. (Arzneimittel-Forschung, 2007)
In mice, Gepon injected into the brain at 0.01-0.1 micrograms was non-toxic. (Voprosy virusologii, 2003)
In lab and animal HSV infection studies, Gepon was non-toxic, without separate safety results for each model. (Voprosy virusologii, 2003)

See every safety result on the Scientific page

Doses studied (5 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
0.1 and 1 mcg/mouse	Animal	mice	Not reported	Not reported	Study in live animals	Barinskiĭ 2003
0.01-0.1 micrograms	Animal	outbred white mice	intracerebral	Not reported	Study in live animals	Gribencha 2003
0.1 microgram	Animal	outbred white mice	intramuscular in the virus locus	Not reported	Study in live animals	Gribencha 2003
6.25 mcg/I	Lab	Not reported	Not reported	Not reported	Study on cells in a dish	Barinskiĭ 2003
1 mcg/mL	Lab	human	Not reported	Not reported	Study on cells in a dish	Ataullakhanov 2002

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official Russian brand label describes local treatment. These instructions do not establish community practice.

Reported routines and cautions

PepBank has no community data on amounts for Gepon yet.

Community sources

No linked source.

plus 1 seller page (not linked)

Gaps

Separate community use was not established.

Questions and more

Ask a question about gepon

The answer links to every study it uses.

What does the evidence say about gepon?Is gepon tested in people?Compare with Thymosin alpha-1 Compare with KPV

Sources

Database: PepBank data for gepon (data version 308560)
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about gepon

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Gepon

Approved in Russia

Also known as HEP-1, Hepon, Heponum, TEKKRRETVEREKE

What it is

Natural fragment, 14 amino acids

Approval

Approved in Russia only

In sport

Status unknown

Studies

12 studies with results. 7 of them gave gepon, with 52 results.
18 in people21 in animals13 in lab cells

Best study in people

Non-randomized trial with 37 people (2007)

Clinical trials

None registered

Dose as reported

Class

Species

Route

Duration

Design

Source

0.1 and 1 mcg/mouse

Animal

mice

Not reported

Study in live animals

Barinskiĭ 2003

0.01-0.1 micrograms

Animal

outbred white mice

intracerebral

Not reported

Study in live animals

Gribencha 2003

0.1 microgram

Animal

outbred white mice

intramuscular in the virus locus

Not reported

Study in live animals

Gribencha 2003

6.25 mcg/I

Lab

Not reported

Study on cells in a dish

Barinskiĭ 2003

1 mcg/mL

Lab

human

Not reported

Study on cells in a dish

Ataullakhanov 2002

Gepon

Gepon at a glance

What is gepon?

Gepon structure and chemistry